D. Jochmans

The triple combination of Remdesivir (GS-441524), Molnupiravir and Ribavirin is highly efficient in inhibiting coronavirus replication in human nasal airway epithelial cell cultures and in a hamster infection model

This paper evaluates a triple antiviral combination's efficacy against coronavirus in cell cultures and a hamster model, finding enhanced antiviral effects even with suboptimal doses.

PIP4K2C inhibition reverses autophagic flux impairment induced by SARS-CoV-2

RMC-113 inhibits PIP4K2C and PIKfyve, reversing SARS-CoV-2-induced autophagic flux impairment and showing antiviral effects.

Yeast-based production platform for potent and stable heavy chain-only antibodies

This paper presents a yeast-based platform for producing stable and potent heavy chain-only antibodies, demonstrating its effectiveness with an anti-SARS-CoV-2 example.

Nirmatrelvir-resistant SARS-CoV-2 is efficiently transmitted in Syrian hamsters

This study shows that nirmatrelvir-resistant SARS-CoV-2 variants replicate and transmit efficiently in Syrian hamsters, highlighting the need for combination therapies to prevent resistance spread.

The substitutions L50F, E166A and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor in vitro and confer resistance to nirmatrelvir

This paper identifies three substitutions in SARS-CoV-2 3CLpro that confer resistance to nirmatrelvir and other 3CLpro inhibitors in vitro.

A SCID mouse model to evaluate the efficacy of antivirals against SARS-CoV-2 infection

This paper establishes a SCID mouse model infected with the SARS-CoV-2 beta B.1.351 variant to evaluate antiviral efficacy, showing significant reduction in viral load with Molnupiravir and Nirmatrelvir.

Ivermectin does not protect against SARS-CoV-2 infection in the Syrian hamster model

This study shows that Ivermectin does not reduce SARS-CoV-2 lung viral load or improve lung pathology in Syrian hamsters and does not enhance Molnupiravir's effect.

Development and optimisation of a high-throughput screening assay for in vitro anti-SARS-CoV-2 activity: evaluation of 5676 phase 1 passed structures

The paper develops a high-throughput screening assay to evaluate 5676 phase 1 compounds for in vitro anti-SARS-CoV-2 activity, identifying eight candidates but finding only remdesivir suitable for further clinical development.

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.

The paper evaluates the antiviral activity of remdesivir, molnupiravir, and nirmatrelvir against SARS-CoV-2 variants, finding they remain effective.

Potent neutralizing anti-SARS-CoV-2 human antibodies cure infection with SARS-CoV-2 variants in hamster model

The paper identifies potent anti-SARS-CoV-2 mAbs that cure infection in hamsters and demonstrates gene-based delivery for in vivo protection against variants.

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.

The Urtica Dioica Agglutinin Prevents Rabies Virus Infection in a Muscle Explant Model

The paper evaluates lectins for anti-rabies virus activity, identifies Urtica dioica Agglutinin (UDA) as effective in preventing RABV infection in a muscle explant model.

Discovery of pan-ErbB inhibitors protecting from SARS-CoV-2 replication, inflammation, and lung injury by a drug repurposing screen

This study identifies lapatinib, an ErbB inhibitor, as a broad-spectrum antiviral that suppresses SARS-CoV-2 and VEEV replication, inflammation, and lung injury through ErbB-mediated mechanisms.

A robust SARS-CoV-2 replication model in primary human epithelial cells at the air liquid interface to assess antiviral agents

This study develops a SARS-CoV-2 replication model using primary human airway epithelial cells to test antiviral agents, finding that remdesivir and interferons inhibit replication while AT-511 does not.

ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model

This study evaluates ALG-097111, a selective SARS-CoV-2 3CLpro inhibitor, showing potent in vitro activity and significant in vivo antiviral effects in Syrian hamsters.

Nelfinavir markedly improves lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect

Nelfinavir reduces SARS-CoV-2-induced lung pathology in Syrian hamsters without affecting viral RNA or infectious titers.

The combined treatment of Molnupiravir and Favipiravir results in a marked potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model

This study shows that combining Molnupiravir and Favipiravir significantly enhances antiviral efficacy against SARS-CoV-2 in hamsters, reducing viral titers by 4.5 log10 and eliminating detectable virus in 60% of treated animals.

Betulonic acid derivatives inhibiting coronavirus replication in cell culture via the nsp15 endoribonuclease

This study identifies betulonic acid derivatives as inhibitors of coronavirus replication by targeting the nsp15 endoribonuclease, with EC50 of 0.6 M against 229E.

In Vitro Activity of Itraconazole Against SARS-CoV-2

This paper assesses the in vitro antiviral activity of itraconazole and its metabolite against SARS-CoV-2, finding EC50 values of 2.3 μM and 3.6 μM, respectively, and reports no clinical efficacy in hospitalized patients.

Identification of TMEM106B as proviral host factor for SARS-CoV-2

This study identifies TMEM106B as a host factor essential for SARS-CoV-2 infection and replication in human cells.

STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters

This study shows that STAT2 signaling both restricts SARS-CoV-2 spread and causes severe pneumonia in infected hamsters.

Differential Antiviral Activities of RSV Inhibitors in Human Airway Epithelium

This study evaluates the antiviral efficacy of RSV inhibitors in a 3D-human airway epithelium model, showing that replication inhibitors are more effective than fusion inhibitors even when treatment is delayed.